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The role of chemotherapy in non-small cell lung cancer (NSCLC)
remains controversial. Although a meta-analysis of randomized
trials in the treatment of inoperable NSCLC has shown a small
survival advantage for cisplatin regimens over best supportive care
(BSC) (NSCLCCG, 1995), treatment remains largely palliative in
intent. In these circumstances, there is a need to balance the bene-
fits of palliative treatment against toxicity, (Brinkley, 1985).
Despite the widely published endorsement of the need to assess
patients’ quality of life (QL) and the availability of appropriate QL
measures, there has been little real commitment to the inclusion of
QL assessment in clinical trials of lung cancer (Hopwood, 1997).
Improvements occur in disease-related symptoms with
chemotherapy, such as MVP mitomycin C, vinblastine, cisplatin
(Fernandez et al, 1989; Hardy et al, 1989) and MIC mitomycin C,
ifosfamide, cisplatin (Cullen 1993), and the relative effectiveness
of these palliative regimens has been compared (Thatcher et al,
1995). It was reported that more patients gain symptomatic benefit
than is suggested by objective tumour response rate. However, a
systematic assessment of QL was not included in these studies
(Thatcher et al, 1997).
Gemcitabine has been evaluated in several phase II studies in
NSCLC. These have shown independently validated objective
response rates ranging from 18–26%, with median survival times
of 6.2–12.3 months (Noble and Goa, 1997). Furthermore, data
suggest that gemcitabine is both better tolerated than cisplatin plus
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Summary Three hundred patients with symptomatic, locally advanced or metastatic NSCLC not requiring immediate radiotherapy were
enrolled into this randomized multicentre trial comparing gemcitabine + BSC vs BSC alone. Patients allocated gemcitabine received 1000
mg/m2 on days 1, 8 and 15 of a 28-day cycle, for a maximum of six cycles. The main aim of this trial was to compare patient assessment of a
predefined subset of commonly reported symptoms (SS14) from the EORTC QLQ-C30 and LC13 scales. The primary end-points were
defined as (1) the percentage change in mean SS14 score between baseline and 2 months and (2) the proportion of patients with a marked
(³ 25%) improvement in SS14 score between baseline and 2 months sustained for ³4 weeks. The secondary objectives were to compare
treatments with respect to overall survival, and multidimensional QL parameters.The treatment groups were balanced with regard to age,
gender, Karnofsky performance status (KPS) and disease stage (40% had metastatic disease). The percentage change in mean SS14 score
from baseline to 2 months was a 10% decrease (i.e. improvement) for gemcitabine plus BSC and a 1% increase (i.e. deterioration) for BSC
alone (P = 0.113, two-sample t-test). A sustained (³ 4 weeks) improvement (³25%) on SS14 was recorded in a significantly higher proportion
of gemcitabine + BSC patients (22%) than in BSC alone patients (9%) (P = 0.0014, Pearson’s chi-squared test). The QLQ-C30 and L13
subscales showed greater improvement in the gemcitabine plus BSC arm (in 11 domains) than in the BSC arm (one symptom item). There
was greater deterioration in the BSC alone arm (six domains/items) than in the gemcitabine + BSC arm (three QL domains). Tumour
response occurred in 19% (95% CI 13–27) of gemcitabine patients. There was no difference in overall survival: median 5.7 months (95% CI
4.6–7.6) for gemcitabine + BSC patients and 5.9 months (95% CI 5.0–7.9) (log-rank, P = 0.84) for BSC patients, and 1-year survival was 25%
for gemcitabine + BSC and 22% for BSC. Overall, 74 (49%) gemcitabine + BSC patients and 119 (79%) BSC patients received palliative
radiotherapy. The median time to radiotherapy was 29 weeks for gemcitabine + BSC patients and 3.8 weeks for BSC. Patients treated with
gemcitabine + BSC reported better QL and reduced disease-related symptoms compared with those receiving BSC alone. These
improvements in patient-assessed QL were significant in magnitude and were sustained. © 2000 Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1307, available online at http://www.idealibrary.com on etoposide (Noble and Goa, 1997) and improves disease-related
symptoms and performance status (Thatcher et al, 1997).
Gemcitabine was therefore an appropriate agent for comparison
against a no-drug control arm using QL outcomes.
In defining a suitable QL end-point, reference was made to the
analysis of QL data from a randomized trial of treatment in NSCLC
conducted by the Medical Research Council Lung Cancer Working
Party, which indicated that respiratory symptoms were necessary
but insufficient for comparing treatment regimens (Hopwood et al,
1995). In 423 patients assessed, the average number of symptoms
at presentation was 13 (two severe, three moderate and eight mild)
and the 10 most prevalent symptoms included not only respiratory
symptoms, but those reflecting general debility (e.g. tiredness, lack
of appetite) and psychological distress.
If improvement in the well-being of lung cancer patients is to be
adequately assessed, the primary trial end-point must include the
impact of treatment on the wide range of symptoms experienced.
Comparison of symptom recording by patients and their treating
doctors has confirmed that doctors underestimate even the most
common symptoms in patients with lung cancer (such as shortness
of breath) (Stephens et al, 1997). QL assessments should be based
on patients’ own ratings. Careful thought should be given to the
optimal time-point for measuring QL outcomes, and to the criteria
on which QL should be compared. This is particularly difficult
given the multidimensional nature of QL and the need to compare
parameters that may change in different directions at different
points in time. Attrition due to patient death and low compliance in
poor performance status patients will limit the amount of evalu-
able QL data and missing data will create difficulties in analysis
(Hopwood, 1996). Moreover, there is no agreed definition of palli-
ation for application in this context (Stephens et al, 1999). These
problems were addressed in the design and implementation of this
trial of chemotherapy plus BSC vs BSC alone. To our knowledge,
this was the first lung cancer treatment trial designed to rely on QL
end-points as the primary outcome measure in a general popula-
tion of NSCLC patients. This trial opened in December 1994.
Since then a randomized trial of the Italian Study Group opened in
April 1996.
METHODS
Patients
Patients with histologically or cytologically proven NSCLC
were eligible if they were previously untreated and had symp-
tomatic locally advanced or metastatic disease which was not
amenable to curative surgery or radiotherapy. Patients had to
have a Karnofsky performance status of 60–90, clinically
measurable disease (uni- or bidimensionally measurable) and
an estimated life expectancy of at least 4 weeks. Patients were
excluded from entry into the study if they needed urgent radio-
therapy, had brain metastases, inadequate bone-marrow
reserve (leucocyte count <3.5 ´ 109 l–1, platelets <100 ´ 109 l–1,
and haemoglobin <100 g l–1), or inadequate liver function
(bilirubin >3 times above normal range; alanine transaminase
or aspartate transaminase >3 times normal (or >5 times normal
in patients with known liver metastases)). Patients had to be
willing and able to complete QL questionnaires and give
written, informed consent. Local ethics committees’ approval
had to be obtained.
Treatment
Patients allocated to gemcitabine + BSC were treated as outpa-
tients with 1000 mg m–2 intravenous gemcitabine over 30 min on
days 1, 8 and 15 of each 28-day cycle for up to six cycles of treat-
ment. Patients were seen weekly during chemotherapy and a full
blood count was performed weekly during the first cycle and every
2 weeks thereafter. In the event of specified World Health
Organization (WHO) grade 3 or 4 toxicities, dose reductions or
omissions were made according to a standardized protocol.
Chemotherapy was stopped in the event of tumour progression,
toxicity or patient request to discontinue therapy. Patients allo-
cated to BSC were seen in the clinic every 4 weeks and were
treated symptomatically; any palliative treatment could be used as
clinically indicated, ideally excluding chemotherapy.
Randomization and masking
Computer generated randomization was performed centrally by
telephone and patients were stratified for the 25 treatment centres,
performance status (KPS 80–90 and 60–70), and disease extent
(locoregional vs metastatic), using an algorithm described by
Pocock and Simon (1975).
Objectives and end-points
The primary objective was to compare gemcitabine plus BSC to
BSC alone with respect to patient assessment of a predefined subset
of 14 commonly reported symptoms (SS14) (see Table 1) from
standardized QL measures, the EORTC QLQ-C30 (Aaronson et al,
1993) and LC13 (Bergman et al, 1994). The end-points used to
assess change in symptoms were: the percentage change in mean
SS14 score from randomization to 2 months; and the proportion of
patients with sustained improvement of SS14 score at 2 months,
defined as a ³ 25% reduction from baseline sustained from month 1
to month 2, and/or from month 2 to month 3.
The secondary objectives were to compare treatment groups
with respect to (1) overall survival, and (2) all QL parameters. In
addition, (3) the objective tumour response rate amongst patients
receiving gemcitabine plus BSC was assessed. The corresponding
end-points were:
1. Time to death. Patients were followed up until the time of
death. Patients alive at the time of data analysis were censored
at the last date they were known to be alive.
2. Patient-assessed QL using all the subscales and symptom
items on the QL measures. Changes from baseline to 2, 4 and
6 months were calculated in terms of the proportion of patients
who improved or deteriorated. Since small differences were
unlikely to reflect clinical benefit, interest was focused on
those subscales or symptom items that showed a ³ 10%
between-treatment difference in the number of patients who
improved or deteriorated.
3. Objective tumour response rate (for the gemcitabine plus BSC
arm only). Tumour response was defined according to WHO
(1979) criteria.
Assessments
Three additional symptom items were included to assess possible
gemcitabine side-effects (skin rash/itchiness, ankle swelling, 
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same way as other items on the EORTC subscales. Patients
completed the EORTC QLQ-C30 and LC13 questionnaires every
4 weeks, prior to their clinical assessment.
A predetermined subset of items (SS14) from the above QL
scales was used for the analysis of the primary end-point (Table 1).
The SS14 included disease-specific items plus the other most
frequently reported symptoms in patients with NSCLC identified
in another patient cohort (Hopwood et al, 1995).
Statistical methods
The study was designed to recruit 300 patients with 150 patients in
each arm. The percentage change in the mean score of the SS14
items in each randomized group, from baseline to 2 months, was
compared using a two sample t-test. The trial was designed so that
the sample size of 150 patients per arm would provide 90% power
to detect a difference of 0.4 SD at the 5% significance level. The
difference in sustained symptom improvement rates was assessed
using Pearson’s chi-squared test. Overall survival curves were
produced using the Kaplan–Meier method, and were compared
using the log-rank test. Baseline QL forms were only included if
completed on or before randomization, but acceptable time
windows of ±1 week were permitted around QL assessment points
of 2, 4 and 6 months.
RESULTS
Trial profile
Three hundred patients from 25 centres were enrolled over 16
months between December 1994 and May 1996. All 300 patients
enrolled were eligible for randomization, with 150 patients in each
arm (Figure 1). One patient was subsequently found to have
mesothelioma but the results presented are on an intent-to-treat
basis. Patients were well matched for pre-treatment characteristics
(Table 2): age, gender, Karnofsky performance status (KPS) and
stage (40% had metastatic disease).
Compliance
Sixty-seven per cent of patients randomized were evaluable for
analysis of QL data with respect to the primary end-point. The
reasons for patients being unevaluable for QL are summarized in
Figure 1. Using available QL data, baseline scores for all QL
subscales and items were compared for the 201 evaluable patients
and 96 patients who did not qualify for this primary analysis.
Unevaluable patients had a greater symptom burden and poorer
function as indicated by a ³ 10-point difference in mean and/or
median scores for the fatigue and social functioning subscales,
appetite loss, constipation and pain (other than chest or shoulder
pain), but were comparable on all other QL domains. Evaluable
patients had greater symptom burden in the cognitive domain.
Therapy received
Patients allocated to gemcitabine received a median of three cycles
(mean 3.2, range 0–6) and 29 (19%) of 150 gemcitabine patients
received six cycles as planned. The mean dose of gemcitabine
delivered in this study was 887 mg m–2, which represents 89% of
the planned dose of 1000 mg m–2. Eight per cent of injections were
omitted and 3% reduced. At disease progression, few patients
received chemotherapy: five BSC patients who progressed at 2,
8.5, 29, 33 and 52 weeks (four had cisplatin combinations; one had
gemcitabine); and three gemcitabine plus BSC patients, who
progressed at 23, 45 and 94 weeks (all re-treated with gemc-
itabine). The patient who received other chemotherapy at 2 weeks
was not eligible for inclusion in the quality-of-life analysis.
Although patients with a need for urgent radiotherapy were
excluded from entry into the study, 74 (49%) patients on gemc-
itabine plus BSC vs 119 (79%) BSC patients received palliative
radiotherapy. At 2 months, 13 (9%) of gemcitabine plus BSC
patients vs 87 (58%) of BSC patients had received radiotherapy.
The median time to radiotherapy was significantly longer for
gemcitabine plus BSC (29.1 weeks) than for BSC (3.8 weeks) (P
<0.001). The indications for palliative radiotherapy were the same
in each arm of the study. Of patients receiving radiotherapy in the
gemcitabine plus BSC arm 54% had the mediastinum and 22% had
the chest treated. In the BSC arm radiotherapy was given to the
mediastinum in 56% and chest in 34% cases.
Primary end-point: SS14
All items on the SS14 were scored in the same direction, with
higher scores representing higher symptom burden. The primary
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Table 2 Characteristics of randomized patients
Gemcitabine plus BSC BSC
Patients randomized 150 150
Female:male 51:99 59:91
Median age (range) 65 (37–82) 64 (32–83)
Karnofsky performance status
60 57 52
70 48 58
80 35 32
90 10 8
Stage
Locally advanced 88 (58.7%) 92 (61.3%)
Metastatic 62 (41.3%) 58 (38.7%)
Table 1 SS14 symptom scale
Original New Question
number in subset
QLQ-C30 number
and LC13
scales
31 1 How much did you cough?
32 2 Did you cough blood?
33 3 Were you short of breath when you rested?
34 4 Were you short of breath when you walked?
35 5 Were you short of breath when you climbed stairs?
40 6 Have you had pain in your chest?
41 7 Have you had pain in your arm or shoulder?
42 8 Have you had pains in other parts of your body?
12 9 Have you felt weak?
18 10 Were you tired?
11 11 Have you had trouble sleeping?
22 12 Did you worry?
13 13 Have you lacked appetite?
16 14 Have you been constipated?objective end-point data were as follows: (1) the percentage
change in mean SS14 score from baseline to 2 months was –10%
(i.e. improvement) for gemcitabine + BSC and +1% (i.e. deteriora-
tion) for BSC (P = 0.113) (Table 3); (2) Sustained (³ 4 weeks)
improvement (³ 25%) in SS14 score was recorded in a signifi-
cantly higher proportion of gemcitabine plus BSC patients (22%)
than in BSC patients (9%) (P = 0.0014, Pearson’s chi-squared test)
(Table 3).
Improvement (³ 25%) in SS14 score at 2, 4 and 6 months
occurred in a greater proportion of patients treated with gemc-
itabine plus BSC than in those receiving BSC alone (Table 3).
Numbers of patients at 4 and 6 months were insufficient to
estimate sustained improvement.
Quality of life
All evaluable EORTC QLQ-C30 and LC13 data were compared
between regimens at 2 and 4 months. Since small differences were
unlikely to reflect clinical benefit, interest was focused on those
subscales or symptom items that showed a ³ 10% between-treat-
ment difference in the number of patients who improved or deteri-
orated.
At 2 months (Figure 2A), of the 25 variables analysed, six
showed between-treatment differences in improvements that were
³ 10%: five of the improvements were greater for gemcitabine
plus BSC (emotional functioning, pain-symptom scale, chest pain,
cough, fatigue), whereas one was greater for BSC (dyspnoea). At 
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Table 3 Patient-assessed symptom scale (SS14)
Gemcitabine BSC P-values
plus BSC
Percentage change in SS14 scores from baseline–2 months
Patients evaluable 99 102
Mean % change –10.2 +1.1 0.113a
Analysis of sustained (³4 weeks) SS14 improvement (³25%)
Patients with sustained improvement 33 (22%) 13 (9%) 0.0014b
Patients with no sustained improvement 117 (78%) 137 (91%)
SS14 improvement (³25%) at 2, 4 and 6 months
2 months
Patients evaluable 99 102
Patients improved 38 (38%) 25 (24%) 0.065b
4 months
Patients evaluable 68 61
Patients improved 30 (44%) 15 (25%) 0.015b
6 months
Patients evaluable 36 40
Patients improved 11 (31%) 9 (22%) 0.644b
aTwo-sample t-test; bPearson’s chi-squared test
300 patients enrolled
300 eligible for randomization
R
150 patients allocated to
gemcitabine + BSC
150 patients allocated to
BSC alone
51 patients did not qualify for primary QL
analysis:
10 did not complete QL forms
     at the specified time-points
22 had died by 2 months
19 had QL forms with missing data
49 patients did not qualify for primary QL
analysis:
16 did not complete QL forms
     at the specified time-points
22 had died by 2 months
19 had QL forms with missing data
99 (66% patients qualified
for primary end-point
(QL) analysis)
102 (68% patients qualified
for primary end-point
(QL) analysis)
Figure 1 Trial profile2 months (Figure 2B), five variables showed between-treatment
differences in deterioration that were ³ 10%: two of the deteriora-
tions were greater for gemcitabine plus BSC (role function and
hair loss), whereas three were greater for BSC (chest pain,
shoulder pain, emotional functioning).
Similarly, at 4 months, six variables showed between-treatment
differences in improvements that were ³ 10%. All six improve-
ments were greater for gemcitabine plus BSC (chest pain, shoulder
pain, emotional functioning, role domain, social domain, financial
impact). Also at 4 months, four variables showed between-treat-
ment differences in deterioration that were ³ 10%: one of the dete-
riorations was greater for gemcitabine plus BSC (hair loss),
whereas three deteriorations were greater for BSC (social domain,
pain-symptom scale, constipation).
Improvements in KPS (lasting at least 4 weeks) were seen in
20.3% of gemcitabine plus BSC patients and in 12.3% of BSC
patients (P = 0.073).
Tumour response
Fifteen gemcitabine plus BSC patients did not have tumour
measurements available due to insufficient therapy (11 patients),
lack of uni- or bidimensional lesions (three patients), and a diag-
nosis of mesothelioma (one patient). Of 135 patients with at least
two assessments of tumour size, 25 patients had objective
responses (overall response rate, 18.5%; 95% CI 13–26).
Survival
As of 4 June 1998, 13 patients were still alive and median follow-
up for these survivors was 25.3 months (range 1.3–40.3 months).
There was no difference in survival between the two arms (Figure
3). Median survival was 5.7 months for gemcitabine plus BSC
patients (95% CI 4.6–7.6) and 5.9 months for BSC (95% CI
5.0–7.9) (log-rank, P = 0.84). Estimated 1-year survival rate was
25% for gemcitabine plus BSC and 22% for BSC. Two-year
survival rate was 6% for gemcitabine plus BSC and 7% for BSC.
Toxicity
The incidence of WHO grade 3 and 4 toxicity in gemcitabine plus
BSC patients was low, as has been reported in phase II studies of
single-agent gemcitabine (Aapro et al 1998): neutropenia 13%,
infection 0.7%, thrombocytopenia 2%, nausea and vomiting 9%,
lethargy 6%, rash 4% and pulmonary toxicity 3%. Patient-reported
symptoms used to assess chemotherapy toxicity showed, as
expected, that patients on the gemcitabine plus BSC arm at 2
months had increased prevalence of hair loss (31% vs 6%), ankle
swelling (30% vs 11%) and flu-like symptoms (32% vs 15%), but
not skin rash (13% vs 16%).
Gemcitabine is a radiosensitizer when given concurrently with
radiation. Radiation was not given concurrently with gemcitabine in
this trial. The Radiation Therapy Oncology Group (RTOG) toxicity
(Cox et al, 1995) was low, grade 3 and 4 pharyngeal/oesophageal
and skin toxicity was ≤ 2% in each arm. RTOG grade 3 and 4
pulmonary toxicity occurred in 4% of BSC patients who received
radiotherapy, but in none of the patients in the gemcitabine plus BSC
arm who subsequently received radiotherapy.
DISCUSSION
The similar survival in the two treatment arms of this randomized
trial highlight the importance of balancing the QL costs and benefits
Gemcitabine-vs-BSC in NSCLC, quality of life 451
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Figure 2 EORTC QLC-C30 and LC13 subscales and items that showed ³10% between-treatment differences in the proportion of patients (A) reporting
improvement from baseline to 2 months (B) reporting deterioration from baseline to 2 months
Figure 3 Kaplan–Meier survival curves for patients in the gemcitabine plus
BSC and BSC armsof chemotherapy in the palliative treatment of NSCLC. Yet, while
the need to evaluate palliative treatments in this way has been
widely advocated, there has been a disappointing level of commit-
ment to the necessary assessments of QL in cancer clinical trials
(Batel-Copel et al, 1997). Our trial, commenced in 1994, attempts
to address this important issue, using QL parameters as the
primary outcome, in order to give a clear focus to the benefit and
impact of treatment in these patients. In 1996 a similar approach
was used in a randomized trial of vinorelbine vs BSC in elderly
patients with advanced NSCLC (ELCVISG, 1999), QL (assessed
using the same scales) and survival were primary outcomes.
Between-treatment differences in the QL domains were reported
using a complex analysis method to adjust for the problem of attri-
tion. However, it is difficult to tease out the level of clinical benefit
from these data as there was significantly more toxicity with hair
loss, constipation and peripheral neuropathy on QL assessment. It
is hoped that other trial groups will add to the experience of QL
assessment in the palliative setting.
Forty per cent of patients in our trial had stage IV disease, and
1-year survival was 25% for gemcitabine plus BSC and 22% for
BSC alone. In a meta-analysis, 1-year survival was 16% for BSC
and 26% for patients treated with cisplatin therapy (NSCLCCG,
1995; Stewart et al, 1994). Our result was in keeping with other
studies. The response rate of 19% was comparable with the lower
range of results from phase II studies of gemcitabine, and probably
reflects efficacy in a less-selected patient group. Indeed, for phase
II studies, entry criteria usually stipulate estimated life expectancy
of ³ 12 weeks, whereas in this study life expectancy had to be ³ 4
weeks. We were surprised at the number of patients in the control
arm requiring early radiotherapy, given that an urgent need for
radiotherapy made patients ineligible for randomization. At the 2-
month QL assessment 58% BSC patients had received radio-
therapy compared with 9% gemcitabine-treated patients.
The results of this study confirm a significant and sustained
improvement in the most prevalent symptoms in NSCLC patients
treated with gemcitabine plus BSC, although the level of improve-
ment varied considerably between different symptom areas,
supporting the need for a broad approach to treatment evaluation.
Disappointingly, breathlessness was not well palliated by gemc-
itabine. This may have been due to increased activity with
improvement in performance status and reduced lethargy, rather
than any pulmonary toxicity, for which the incidence was low (3%
gemcitabine plus BSC patients experienced WHO grade 3 and 4
toxicity and 4% BSC patients treated with radiotherapy had RTOG
grade 3 and 4 toxicity). It is of concern that overall, only one-fifth
to one-third of these trial patients gained relief from common
disease-related symptoms such as chest pain, cough or dyspnoea.
Interestingly, fatigue improved in both arms of the trial, despite
frequent expectations that chemotherapy and/or radiotherapy will
affect this adversely. Gemcitabine plus BSC had the most marked
benefit on emotional functioning, suggesting that active, systemic
treatment is more acceptable to patients than is often assumed.
The practical problems for investigators researching QL in the
palliative setting have been well described (Hopwood et al 1994;
Hopwood, 1996; Thatcher et al, 1997). Of particular concern is
patient attrition and the risk of bias if ill patients are unable to
complete QL forms or staff are unwilling to approach them
(Hopwood et al, 1998). Careful attention was given to these
aspects during the planning and implementation of this study to
optimize data collection, and considerable additional resources
were required to achieve this. The proportion of patients with
evaluable baseline and 2-month data (66%) is probably realistic
for any study of this type (given minimal expected survival of 1
month), and an improvement on others (Bernhard and Gelber,
1998). Reassuringly, missing data do not appear to have intro-
duced bias into the resulting comparison. Moreover, the applica-
tion of tight time-windows enabled us to keep random and
non-random bias to a minimum, and we feel confident that the
results are an accurate reflection of the patients assessed.
Controversy continues as to whether QL outcomes should be
summarized, to simplify analysis and reporting (Barsevik et al,
1997; Billingham et al, 1997) at the risk of being clinically unin-
terpretable, or remain disaggregated, to provide a breadth of infor-
mation which may, however, be difficult to present and absorb
(MRC LCWP 1996a; 1996b; Harper et al, 1997). Both approaches
are numerically driven and may suffer from lack of clear indicators
of clinical benefit. In this trial we created a short-scale of the most
prevalent symptoms, for the purpose of analysis, to address the
need for clinical relevance in demonstrating palliation in several
symptom domains without reliance on multiple subscales.
Comparing the proportions of patients improving by a predeter-
mined amount on this scale enabled us to provide a clinically inter-
pretable outcome. While not a perfect solution, we think this
method warrants replication.
The collection of QL data for use as a primary outcome proved
feasible within a UK multicentre setting, but the resources needed
to ensure good-quality QL data are considerable. Funding agen-
cies need to be prepared to support these costs in clinical trials’
budgets, if reliable QL outcomes are required, and if the invest-
ment of the past two decades in QL methodology is to bear fruit.
Although it may have been desirable to measure the primary end-
point later in this trial, the further expected attrition would have
required a substantially increased sample size.
Patient-rated QL data showed that improvements were signifi-
cant in duration and magnitude in the chemotherapy arm, together
with improved performance status as measured by clinicians and a
reduced need for palliative radiotherapy. Since our trial
commenced we are aware of one other study which has used
quality of life as a primary outcome measure (ELCVISG, 1999).
We would advocate this approach in other palliative trials, in order
to address the impact on important aspects of patient well-being
and challenge inappropriate assumptions.
The results of this study showing quality of life benefit, the
Italian study showing improved survival, cognitive function, dysp-
noea and pain in elderly patients, and a study from Billingham et al
(1997) showing improved survival and quality of life score with
cisplatin combination chemotherapy vs BSC, suggest that appro-
priate patients should be offered palliative chemotherapy rather
than entered into randomized trials containing a best supportive
care arm.
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